FAK received research funding from Bayer, Bristol Myers Squibb, Boston Scientific, AstraZeneca, Merck Sharp & Dohme, Leo Pharma, Actelion, Farm-X, The Netherlands Organisation for Health Research and Development, The Dutch Heart Foundation, and the Horizon Europe Program, all outside this work and paid to his institution. SCW received research funding from Janssen paid to his employer without direct salary benefit or support, all outside this work and paid to his institution. AS received consulting fees from Novartis outside of this work and is Co-Chair of the Vasculearn Network Medical Advisory Board. PA received research funding from Novo Nordisk, Sanofi, and Spark Therapeutics, and is President of the International Society on Thrombosis and Haemostasis. JH has received consulting fees from Elvium, Otsuka, Eli Lilly, Boehringer Ingelheim, HLS Therapeutics, Eisai, and Idorsia and honoraria from MDBriefcase, Liv, MedPlan, Master Clinician Alliance, Academy, Bridge, PeerVoice, Seacourses, Thrombosis Canada, Meducom, Canadian Heart Research Centre, Continuing Professional Development Network, create to communicate Medical Communications, STA HealthCare Communication, collaborative CME and Research Network, Telus Health, EOCI Pharmacomm, AgenceUnik, Humber Hospital, Alliance for Best Practices in Health Education, and The Canadian Society of Endocrinology and Metabolism; he has participated in Data Safety Monitoring Boards for Boehringer Ingelheim, Eli Lilly, Elvium, Takeda, Bausch, AstraZeneca, Novartis, Lundbeck, Novo Nordisk, Janssen, Eisai, HLS Therapeutics, Otsuka, Idorsia, Pfizer, Amgen, AbbVie, GlaxoSmithKline, Bayer, and Valeo. RH received honoraria from Pfizer and Biogen and support for attending the Multiple Sclerosis Research Organisation UK. JAK received research funding from the National Institutes of Health, Centers for Disease Control and Prevention, and Human Animal Bond Research Institute, all paid to his institution, payment for expert testimony for medical malpractice cases, and is on the Board of Directors at the PERT Consortium. SN received payment from Leo Pharma to support research staff and is a Medical Director and Trustee at Thrombosis UK. TR received research funding from National Institute for Health and Care Research Efficacy and Mechanism Evaluation, National Health and Medical Research Council, and Australian and New Zealand Society for Vascular Surgery university grants, honoraria from Pharmacosmos and Metagenics, support for meetings and travel, and receipt of equipment from Radiometer; has participated in Data Safety Monitoring Boards for SPACE RCT and INTACT and the Advisory Board for Pharmacosmos; holds leadership or board roles for National Association of Testing Authorities, Australia and The Royal Australasian College of Surgeons and serves on the Trial Steering Committee for POISE 3, ECST 2, GLAD, and FUNNY; and is the Director of The Iron Clinic and VeinCare London and the Vascular lead for 18-Week Support. ATCR received honoraria from Sanofi. GLG received honoraria from Aspen Pharma, Emcure, Pfizer, and Sanofi. All other authors declare no competing interests. FAK and DL were supported by the Dutch Thrombosis Foundation. GLG holds the Chair on Diagnosis of Venous Thromboembolism from the Department of Medicine, University of Ottawa. SN holds a Marie Curie Chair in Supportive and Palliative Medicine. We thank Vasculearn Network for their invaluable comments and support during this work. This work was supported by corporate sponsorship from Bristol Myers Squibb and Pfizer to Vasculearn Network. The funder of this work had no role in the development of the toolkit or the writing of this In Focus. No honoraria were paid to panel members.